Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Non-inferiority REal-world Evidence Study Comparing the Effectiveness of Subcutaneous Infliximab MONOtherapy and Subcutaneous Infliximab Combined With Immunosuppressive Therapy in Patients With Crohn's Disease and Ulcerative Colitis.

NCT07564609 is registered in ClinicalTrials.gov with University Hospital, Clermont-Ferrand as lead sponsor.

NCT NCT07564609
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07564609 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Non-inferiority REal-world Evidence Study Comparing the Effectiveness of Subcutaneous Infliximab MONOtherapy and Subcutaneous Infliximab Combined With Immunosuppressive Therapy in Patients With Crohn's Disease and Ulcerative Colitis.
Lead sponsor
University Hospital, Clermont-Ferrand
Phase
Observational
Overall status
Enrolling by invitation
Start date
August 1, 2025
Completion date
October 31, 2026
Enrollment
420 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

crohn disease (cd), ulcerative colitis (uc)